BioSpace News Archive

Erasca, Inc., a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, announced the company will present a poster presentation at the upcoming American Association for Cancer Research Annual Meeting, taking place April 14-19, 2023, in Orlando, Florida.

Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), today announced its decision to discontinue its ongoing Phase 1/2 clinical trials evaluating the safety and preliminary efficacy of its GoCAR-T cell product candidates in combination with rimiducid in heavily pre-treated cancer patients.

23andMe Holding Co. announced that clinical data from the Phase 1 portion of the Phase 1/2a study of 23ME-00610 has been selected for a poster presentation at the American Association for Cancer Research Annual Meeting being held in Orlando, Florida, April 14-19, 2023.

Senti Biosciences, Inc., a biotechnology company innovating next-generation cell and gene therapies using its proprietary gene circuit platform, announced the acceptance of three abstracts for presentation at the American Association for Cancer Research Annual Meeting being held April 14-19, 2023, in Orlando, Florida.

Immuneering Corporation (Nasdaq: IMRX) announced today that it will be presenting data on its lead program IMM-1-104 at the American Association for Cancer Research (AACR) annual meeting, held April 14-19 in Orlando, Florida.

Merus N.V. announced the publication of an abstract highlighting the preclinical evaluation of the bispecific antibody MCLA-129 for poster presentation at the American Association for Cancer Research Annual Meeting 2023 taking place in Orlando, Florida April 14-19, 2023.

Notable Labs, Inc. (“Notable”) today announced that results from a clinical validation study of its Predictive Precision Medicine Platform (PPMP) will be presented at the 2023 American Association for Cancer Research (AACR) Annual Meeting being held in Orlando, Florida on April 14-19, 2023.

HotSpot Therapeutics, Inc. today announced it will present two poster presentations on the company’s CBL-B program at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19, 2023, in Orlando, FL.

Elevation Oncology, Inc. (Nasdaq: ELEV) today announced that preclinical proof-of-concept data for EO-3021 will be highlighted in an oral presentation at the New Drugs on the Horizon special session at the American Association for Cancer Research (AACR) Annual Meeting 2023, being held April 14-19, 2023 in Orlando, Florida.

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced publication of abstracts at the 2023 Annual Meeting of the American Association for Cancer Research.